Abstract
Atherosclerosis, the primary cause of cardiovascular disease, is a complex and multifactorial pathology resulted from the harmful interactions between genetic and environmental factors. There is a growing body of evidence in support of the role of mitochondrial factors in the pathogenesis of atherosclerosis. Impaired mitochondrial function and structural and qualitative changes in mitochondrial components such as mitochondrial DNA (mtDNA) damage may be directly involved in the development of multiple mechanisms of atherogenesis. Recent findings show that several heteroplasmic mutations of mtDNA are related to atherosclerosis, coronary heart disease and several atherosclerosis-related diseases such as arterial hypertension and diabetes mellitus. Therefore, heteroplasmic mtDNA mutations could represent a promising molecular biomarker of genetic susceptibility to atherosclerosis and related pathologies. This review is focused on the latest findings in the studies of mutations of mitochondrial genome, which are associated with atherosclerosis and atherosclerosis- related diseases.
Keywords: Atherosclerosis, atherogenesis, mitochondrial DNA, mutations, heteroplasmy, coronary heart disease.
Current Pharmaceutical Design
Title:Mutations of Mitochondrial DNA in Atherosclerosis and Atherosclerosis-Related Diseases
Volume: 21 Issue: 9
Author(s): Igor A. Sobenin, Andrey V. Zhelankin, Konstantin Y. Mitrofanov, Vasily V. Sinyov, Margarita A. Sazonova, Anton Y. Postnov and Alexander N. Orekhov
Affiliation:
Keywords: Atherosclerosis, atherogenesis, mitochondrial DNA, mutations, heteroplasmy, coronary heart disease.
Abstract: Atherosclerosis, the primary cause of cardiovascular disease, is a complex and multifactorial pathology resulted from the harmful interactions between genetic and environmental factors. There is a growing body of evidence in support of the role of mitochondrial factors in the pathogenesis of atherosclerosis. Impaired mitochondrial function and structural and qualitative changes in mitochondrial components such as mitochondrial DNA (mtDNA) damage may be directly involved in the development of multiple mechanisms of atherogenesis. Recent findings show that several heteroplasmic mutations of mtDNA are related to atherosclerosis, coronary heart disease and several atherosclerosis-related diseases such as arterial hypertension and diabetes mellitus. Therefore, heteroplasmic mtDNA mutations could represent a promising molecular biomarker of genetic susceptibility to atherosclerosis and related pathologies. This review is focused on the latest findings in the studies of mutations of mitochondrial genome, which are associated with atherosclerosis and atherosclerosis- related diseases.
Export Options
About this article
Cite this article as:
Sobenin A. Igor, Zhelankin V. Andrey, Mitrofanov Y. Konstantin, Sinyov V. Vasily, Sazonova A. Margarita, Postnov Y. Anton and Orekhov N. Alexander, Mutations of Mitochondrial DNA in Atherosclerosis and Atherosclerosis-Related Diseases, Current Pharmaceutical Design 2015; 21 (9) . https://dx.doi.org/10.2174/1381612820666141013133000
DOI https://dx.doi.org/10.2174/1381612820666141013133000 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ethnicity and Drug Therapy for Hypertension
Current Pharmaceutical Design Molecular Genetics of Abdominal Aortic Aneurysm: Therapeutic Implications
Current Pharmacogenomics and Personalized Medicine Interactions of VIP, Secretin and PACAP1-38 with Phospholipids: A Biological Paradox Revisited
Current Pharmaceutical Design Editorial from Editor-in-Chief (Novel Oral Anticoagulants in the Treatment of Pulmonary Embolism: Are We There Yet?)
Current Respiratory Medicine Reviews Sildenafil in Combination Therapy against Cancer: A Literature Review
Current Medicinal Chemistry A Hopeful Prospect of Riociguat as a Soluble Guanylate Cyclase Stimulator for Management of Pressure Ulcers
Current Drug Discovery Technologies Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus
Current Pharmaceutical Design From Anti-allergic to Anti-Alzheimer ’ s: Molecular Pharmacology of Dimebon™
Current Alzheimer Research MiR-106a Associated with Diabetic Peripheral Neuropathy Through the Regulation of 12/15-LOX-meidiated Oxidative/Nitrative Stress
Current Neurovascular Research Transdermal Delivery of AT1 Receptor Antagonists Reduce Blood Pressure and Reveal a Vasodilatory Effect on Kidney Blood Vessels
Current Molecular Pharmacology Nesfatin/Nucleobindin-2 (NUCB2) and Glucose Homeostasis
Current Hypertension Reviews Microalbuminuria: A Neglected Cardiovascular Risk Factor in Non-diabetic Individuals?
Current Pharmaceutical Design Patent Selections
Recent Patents on Cardiovascular Drug Discovery An 8-Year Retrospective Study of Human Visceral Leishmaniasis
Current Clinical Pharmacology Targeting Microparticle Biogenesis: A Novel Approach to the Circumvention of Cancer Multidrug Resistance
Current Cancer Drug Targets Leptin and Inflammation
Current Immunology Reviews (Discontinued) Chemical and Biological Aspects of the Genus Verbesina
The Natural Products Journal Value of Sodium-Glucose Co-Transporter 2 Inhibitor Versus Traditional Medication in Microalbuminuric Diabetic Patients
Current Diabetes Reviews Anti-HER2 Therapy in Elderly Breast Cancer Patients
Reviews on Recent Clinical Trials Losartan Chemistry and Its Effects via AT1 Mechanisms in the Kidney
Current Medicinal Chemistry